Fathom Therapeutics Raises $47 Million to Advance AI Drug Design Platform
Fathom Therapeutics, formerly Atommap Corp., has secured $47 million in an oversubscribed Series A round led by Sutter Hill Ventures. The company uses quantum chemistry and AI through its Microcosmos platform to design small molecule drugs and will use the funds to expand lab and discovery programs.